secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0000950170-24-121088
Event type: earnings
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics discusses Q3 results and ASH abstracts on investor call
-------------------------------------------------------------------------

- Investor presentation covered Q3 financial results, but no specific figures provided in filing.
- Presented preclinical and clinical data from ASH abstracts, including ESCAPE and BEAM-101.
- Company reiterated sickle cell disease strategy and provided business update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024121088/0000950170-24-121088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024121088/beam-20241105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-121088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer